Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

Research output: Contribution to journalReview articlepeer-review

Abstract

The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

Original languageEnglish
Pages (from-to)103203
JournalCritical Reviews in Oncology/Hematology
Volume158
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Anti-Bacterial Agents/therapeutic use
  • Anti-Infective Agents/therapeutic use
  • Humans
  • Lymphoproliferative Disorders/drug therapy

Fingerprint Dive into the research topics of 'Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper'. Together they form a unique fingerprint.

Cite this